אקטיק 600 מקג Israel - Hebräisch - Ministry of Health

אקטיק 600 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 600 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

אקטיק 1200 מקג Israel - Hebräisch - Ministry of Health

אקטיק 1200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 1200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

פסנרה Israel - Hebräisch - Ministry of Health

פסנרה

astrazeneca (israel) ltd - benralizumab - תמיסה להזרקה - benralizumab 30 mg / 1 ml - benralizumab

נוקספיל תרחיף Israel - Hebräisch - Ministry of Health

נוקספיל תרחיף

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

מגה דנט נגד פלאק Israel - Hebräisch - Ministry of Health

מגה דנט נגד פלאק

איינשטיין צור יבוא ויצוא וסחר בינלאומי בעמ - היגיינת הפה

מגה דנט נגד עששת Israel - Hebräisch - Ministry of Health

מגה דנט נגד עששת

איינשטיין צור יבוא ויצוא וסחר בינלאומי בעמ - היגיינת הפה

ג'ל ניקוי אנטי-אייג'ינג Israel - Hebräisch - Ministry of Health

ג'ל ניקוי אנטי-אייג'ינג

קוסמטיקום בעמ - תכשיר ניקוי העור

קורקטיב אנטי אייג'ינג מסק Israel - Hebräisch - Ministry of Health

קורקטיב אנטי אייג'ינג מסק

ריבה קוסמטיקס בעמ - צמצום קמטים וקמטוטים

לקסיבה Israel - Hebräisch - Ministry of Health

לקסיבה

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

לקסיבה Israel - Hebräisch - Ministry of Health

לקסיבה

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.